BMS + bluebird bio file BLA at FDA for idecabtagene vicleucel to treat multiple myeloma patients who have received at least three prior therapies.
Related news and insights
Oncopeptides AB (publ) announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti (melphalan flufenamide, also called melflufen) in EU.
Pfizer Inc. announced new data from a planned interim analysis of the Phase II MagnetisMM-3 registration-enabling trial of elranatamab in people with relapsed/refractory multiple myeloma (RRMM) whose disease is refractory to at least one agent in each of three major classes of medications approved for the disease.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/II MajesTEC-1 study .